SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is currently experiencing high volatility as investors weigh President Trump's recent vocal endorsement of the company's defense capabilities against a persistent short thesis led by Michael Burry. The community remains deeply divided, with bulls pointing to the company's strategic entrenchment in military operations as a long-term moat, while bears continue to pressure the stock based on valuation concerns and competitive threats in the AI software sector.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively hyping the project's multichain capabilities and deflationary burn mechanism, positioning it as a standout meme coin against broader market uncertainty. Supporters are rallying around the token's organic growth and viral branding, often comparing it to established market leaders to drive momentum.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community speculation following a rapid valuation surge that has triggered massive liquidations of short positions. The discussion is sharply divided between believers in the project's decentralized music-event utility and skeptics who are warning of a potential pump-and-dump scheme.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a focal point of intense community discussion, driven by its ongoing ecosystem expansion and a surge in speculative interest surrounding new token launches on the network. Traders remain deeply divided, with some actively building long-term positions while others engage in highly leveraged short-term plays, mirroring the broader market's heightened sensitivity to macroeconomic and geopolitical volatility.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is rallying as the market responds to a massive multi-year infrastructure deal with Meta, now valued at over $20 billion, alongside a newly announced agreement to support Anthropic's Claude AI models. Community sentiment remains intensely focused on the company's aggressive capital expansion through convertible notes and its ability to secure structural partnerships with major AI labs, fueling active debate regarding the balance between rapid growth and potential share dilution.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging to all-time highs as investors pile into the AI infrastructure trade, fueled by massive contract wins, analyst upgrades, and optimism surrounding potential AI-focused acquisitions. The community is actively debating the stock's valuation parity with peers, with many bulls pointing to strong fundamental catalysts as a justification for further upside, while others caution against the potential for near-term pullbacks due to the rapid price appreciation.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfer is gaining momentum as investors eye its strategic role in supplying natural gas to the rapidly growing AI data center sector and upcoming earnings. The community is actively discussing the stock's potential for a breakout, with many focusing on long-term accumulation and the reliability of its dividend distributions amid broader energy market volatility.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently navigating a period of heightened market sensitivity, with investors closely watching geopolitical tensions and ongoing diplomatic negotiations that continue to influence broader crypto sentiment. The community remains divided, with some traders highlighting the potential for volatile price swings while others focus on the asset's long-term utility and its role within the evolving digital finance landscape.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM shares experienced a sharp decline following an Anthropic blog post detailing new AI capabilities for COBOL modernization, which investors fear could disrupt the company's legacy mainframe services. Despite this, many market participants and analysts view the sell-off as an overreaction, noting that IBM is already integrating AI into its own secure, governed platforms to modernize enterprise infrastructure rather than abandon it.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently experiencing intense volatility fueled by massive investor interest in the semiconductor and photonics sectors, with the community actively debating whether the stock's parabolic climb is a sustainable re-rating or an overextended bubble primed for a sharp correction. Much of the discourse centers on conflicting narratives regarding the company's valuation versus its role in critical AI infrastructure, leading to a high-stakes standoff between retail bulls betting on long-term hyperscaler growth and bears focusing on insider selling and potential dilution risks.

statis crypto Watchlist

Bitcoin

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The private placement, worth $4 million, is expected to close around April 7th.&nbsp;</li><li>Focus Universal said that the offering consisted of the sale of about 1.12 million common units, each comprising either a share or a pre-funded warrant, plus Series A and Series B warrants to buy shares at $3.33.&nbsp;</li><li>The company said that it expects to use the net proceeds from the offering for general corporate purposes and working capital.</li></ul>Shares of Nevada-based Focus Universal Inc. (FCUV) rallied more than 67% on Monday after the company announced a private placement worth $4 million.Focus Universal, which provides patented hardware and software design technologies, said that it had entered into definitive agreements with institutional investors for the private placement of its common stock and pre-funded and investor warrants at a price of $3.58 per share.The transaction is expected to close around April 7, the company said.<h2 class="st-heading-2">Private Placement Details</h2>Focus Universal said that the offering consisted of the sale of about 1.12 million common units, each comprising either a share or pre-funded warrant, plus Series A and Series B warrants to buy shares at $3.33.Each unit was priced at $3.58, or at about $3.579 for pre-funded units, equal to the offering price per common share minus an exercise price of $0.00001 per pre-funded warrant.The company said that the pre-funded warrants are immediately exercisable with no expiry. Series A warrants, with an initial exercise price of $3.33 per share would also be exercisable immediately and expire in 24 months, while Series B warrants will expire in 60 months. Each pre-funded unit replaces one common unit in the offering structure.Focus Universal said that it expects to use the net proceeds from the offering for general corporate purposes and working capital.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FCUV shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours.Meanwhile, message volumes surged from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/FCUV">FCUV stock</a> has lost about 36% so far this year.Meanwhile, <a href="https://stocktwits.com/symbol/IWC">iShares Micro-Cap ETF</a> (IWC), which tracks micro-capitalization U.S. companies, has risen about 3.25% in the same time.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/plug-stock-rises-most-in-a-month-retail-turns-bullish-on-hydrogen-deal/cZJ4HG3RIYm">PLUG Stock Rises Most In A Month — Retail Turns Bullish On Hydrogen Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is FCUV Stock Surging More Than 67% Today?

Nevada-based Focus Universal on Monday announced that it had entered into definitive agreements with institutional investors for the private placement of its common stock, and pre-funded and investor warrants. 

This Micro-Cap Tech Stock Surged More Than 67% Today — Here’s Why

Equity

<ul class="summary-bullets"><li>The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.</li><li>Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.</li><li>In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.</li></ul>Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OTLK">Outlook Therapeutics</a> trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">Why Did Outlook Therapeutics Announce The Offering?</h2>Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Outlook Therapeutics’ proposed offering was&nbsp;criticized&nbsp;by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.<stembedurl>https://stocktwits.com/HarveySpecter20/message/648356634</stembedurl>Another user highlighted the lack of data on the uptake of the investigational treatment from patients.<stembedurl>https://stocktwits.com/updownsides/message/648355300</stembedurl><a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fidelity-backs-elon-musk-tesla-spacex-terafab-project-datacenters-in-space/cZ3mK7PRI0u">Elon Musk's Joint Tesla, SpaceX Terafab Project Makes A 'Ton Of Sense', Says Investor Fidelity: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is OTLK Stock Falling Today?

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

<ul class="summary-bullets"><li>Apollo intends to stick to the same cap next quarter as it balances “the interests of shareholders seeking liquidity with those who choose to remain invested,” per the letter.&nbsp;</li><li>The firm expects the granted redemptions to amount to roughly $730 million of gross outflows for the first quarter.</li><li>Apollo Debt Solutions is returning less cash to clients than some of its peers that capped withdrawals, the report said.&nbsp;&nbsp;</li></ul>Apollo Global Management is reportedly curbing redemptions from one of its largest non-traded private credit funds for retail investors, sending shares down nearly 3% in extended hours of trading.&nbsp;The $25 billion business development company, Apollo Debt Solutions, capped withdrawals at 5% of outstanding shares Monday after clients sought to redeem 11.2%, according to a report from Bloomberg News that cited a shareholder letter.&nbsp;<h2 class="st-heading-2">Details</h2>With redeeming investors receiving just 45% of their capital, Apollo Debt Solutions is returning less cash to clients than some of its peers that capped withdrawals, the report said.&nbsp;&nbsp;Apollo intends to stick to the same cap next quarter as it balances “the interests of shareholders seeking liquidity with those who choose to remain invested,” per the letter. Apollo, which has been pushing for more transparency in private markets, reportedly said that Apollo Debt Solutions had returned 1% over the past three months.&nbsp;The firm expects the granted redemptions to amount to roughly $730 million of gross outflows for the first quarter, offsetting the roughly $724 million of inflows for the period, the report said.&nbsp;<h2 class="st-heading-2">Private Sector Reeling</h2>The private credit industry has been seeing a rise in redemption rates across several funds over fears about the asset class, as well as its exposure to software businesses, which are at risk of AI-related disruption.Blue Owl earlier said that it will permanently stop allowing redemptions from Blue Owl Capital Corp. II, a semi-liquid private credit fund marketed to U.S. retail investors.Blackstone’s $82 billion Blackstone Private Credit Fund (BCRED) disclosed a rise in redemption rates. BCRED’s first-quarter (Q1) redemption requests totaled 7.9% of the outstanding shares, up from 4.5% in Q4.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around APO trended in ‘bearish’ territory amid ‘normal’ message volume.&nbsp;Shares in the company have fallen 24% so far in 2026.&nbsp;

 In this photo illustration, the Apollo Global Management company logo is seen displayed on a smartphone screen.

Apollo Reportedly Caps Private Credit Fund Withdrawals; Stock Dives

The $25 billion business development company, Apollo Debt Solutions, capped withdrawals at 5% of outstanding shares Monday after clients sought to redeem 11.2%, according to a report from Bloomberg News. 

<ul class="summary-bullets"><li>The company stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.</li><li>Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.</li><li>The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.</li></ul>Unusual Machines Inc. (UMAC) on Friday announced the pricing of its public offering to raise $150 million, which includes a strategic investment from Ondas Inc. (ONDS).Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.<a href="https://stocktwits.com/symbol/UMAC">Unusual Machines shares</a> were down more than 13% in Friday’s opening trade. Retail sentiment on Stocktwits about the company trended in ‘bearish’ territory, while message volume was at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Will UMAC Use These Funds For?</h2>Unusual Machines stated in its announcement that it intends to use the funds raised through this stock offering to acquire additional inventory, for working capital needs, and for general corporate purposes.“We approach capital the same way we approach operations, deliberately and with a clear plan for deployment. This raise allows us to expand inventory, support production, and continue building a reliable, U.S.-based supply chain for drone components,” said Unusual Machines CEO Allan Evans.President Donald Trump’s son, Donald Trump Jr., who is on the company’s advisory board, said that the latest capital infusion will enable Unusual Machines to build the foundation for a strong domestic drone industry.<h2 class="st-heading-2">What Does Unusual Machines Do?</h2>Unusual Machines manufactures and sells drone components and drones. It also sells small acrobatic first-person-view (FPV) drones and equipment directly to consumers.The Florida-based company announced a public offering on Thursday to expand its U.S. drone parts inventory and for working capital and general corporate purposes.<a href="https://stocktwits.com/symbol/UMAC">UMAC stock</a> is up 127% year-to-date, while ONDS stock is up 4%. The SPDR S&amp;P Kensho New Economies Composite ETF (KOMP) is up 23% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 35%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fedex-beat-and-raise-q3-wall-street-price-target-hikes-for-fdx-stock/cZ3Xqp2RILh">FedEx's Beat And Raise Q3 Earns Street Accolades As Price Target Hikes Pour In — Analysts Flag 'Unique Combination' Of Price And Yield Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is UMAC Stock Falling Today?

Unusual Machines stated that it will issue 8.8 million shares at $17 apiece, a discount of more than 9% to the stock’s closing price on Thursday.

<ul class="summary-bullets"><li>Palladyne stated that the ALRRM is capable of exceeding a distance of 350 nautical miles at an unspecified but high altitude.</li><li>This missile can cover this distance at a sustained cruise speed of beyond the required Mach 4.0.</li><li>Palladyne also stated that the ALRRM can deliver a 150-lb warhead air-breathing solid-fuel ramjet.</li></ul>Palladyne AI Corp. (PDYN) on Wednesday announced that its subsidiary has been awarded a contract by the U.S. Navy to develop new air-launched, near-hypersonic, long-range, low-cost missiles.Palladyne’s subsidiary GuideTech will develop the new Air-Launched Rapid Response Missile (ALRRM). The company said that ALRRM is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.<a href="https://stocktwits.com/symbol/PDYN">Palladyne AI shares</a> were up more than 15% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory. PDYN was the second most trending ticker on the platform at the time of writing.<h2 class="st-heading-2">What Is ALRRM Capable Of?</h2>Palladyne stated that the ALRRM is capable of exceeding a distance of 350 nautical miles at an unspecified but high altitude. This missile can cover this distance at a sustained cruise speed of beyond the required Mach 4.0. Palladyne also stated that the ALRRM can deliver a 150 lb warhead air-breathing solid fuel ramjet (SFRJ).“The 2025 National Security Strategy explicitly states that the U.S. must build ‘next-generation missiles with a clear and urgent need for cost-effective, high-performance strike capabilities’ for the U.S. military,” said Palladyne AI CEO Ben Wolff.Wolff added that the ALRRM can deliver on these strategic needs at a fraction of the cost.“We believe there is no other missile currently available to the U.S. military that combines the speed, range, and payload capacity of the ALRRM, at this size and price point — creating a new strike class for 5th gen fighters that is stealth-borne, near-hypersonic, and deep-theater strike,” he added.This comes amid the ongoing Iran war, with the U.S. having incurred over $11 billion in the first week of the conflict. The Trump administration could reportedly seek an additional funding of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-warns-debt-risk-trump-seeks-50b-for-iran-war/cZ3EEoORIXe">$50 billion</a> to replenish the weapons stockpile of the U.S.<h2 class="st-heading-2">What Does Palladyne AI Do?</h2>Palladyne AI is a Salt Lake City, Utah-based company developing AI and autonomy solutions, advanced avionics and more for the defense and industrial markets.Earlier this month, the company reported a loss of $0.16 per share on revenue of $1.66 million, while Wall Street expected a loss of $0.14 per share on revenue of $0.81 million, according to Fiscal.ai data.<a href="https://stocktwits.com/symbol/PDYN">PDYN stock</a> is up 59% year-to-date, but down 12% over the past 12 months. The iShares Micro-Cap ETF (IWC) is up 39% over the past 12 months, while the Themes Generative Artificial Intelligence ETF (WISE) is up 1%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/will-fed-consider-rate-hikes-strategist-warns-inflation-worse-amid-iran-war/cZ37Bn2RIgW">Will The Fed Consider Rate Hikes Again? Strategist Warns Inflation Picture Could 'Get A Lot Worse' Amid Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Palladyne AI Corp. logo is seen displayed on a smartphone screen. 

Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market

The company said that the Air-Launched Rapid Response Missile is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.

<ul class="summary-bullets"><li>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.</li><li>The company also stated that the Phase III trial results are trending in line with those from the Phase IIb trial.</li><li>Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.</li></ul>Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Results Show About 70-80% Reduction In Recurrence Rate, Says Greenwich</h2>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.The company also stated that the results of the Phase III trial are trending in line with those from the Phase IIb results. Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.However, Greenwich stated that these Phase III trial results are still preliminary and that the final analysis may differ.The Phase III FLAMINGO-01 trial is designed to evaluate the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients with residual disease or high-risk pathological complete response who have completed neoadjuvant and adjuvant trastuzumab-based therapy.<h2 class="st-heading-2">What Does Greenwich LifeSciences Do?</h2>Greenwich LifeSciences is a clinical-stage biopharmaceutical company based out of Stafford, Texas. It is currently focused on the development of GP2, which is an immunotherapy to prevent breast cancer recurrence in patients who have previously undergone surgery.<a href="https://stocktwits.com/symbol/GLSI">GLSI stock</a> is up 34% year-to-date and 134% over the past 12 months. The iShares Russell 2000 Growth ETF (IWO) is up 22% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-fed-chair-powell-should-cut-rates-right-now/cZ3PPPaRIfw">Trump Says Fed Chair Powell Should Cut Rates Right Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

<ul class="summary-bullets"><li>The company said upon closing of the final transaction it will result in the cancellation of 1.34 million units of its publicly-traded senior notes across multiple outstanding series.</li><li>RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash.</li></ul>BRC Group Holdings shares rallied more than 6% in extended hours of trading on Thursday after it announced a series of senior note transactions with an institutional investor, resulting in reduction of some of its debt.&nbsp;The company said that the closing of the final transaction will result in the cancellation of 1.34 million units of its publicly-traded senior notes across multiple outstanding series in exchange for the issuance of an aggregate of 4.2 million shares of its common stock at an average price of $7.0933 per share.<h2 class="st-heading-2">Details</h2>RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash. Upon closing of the final transaction scheduled for March 13, 2026, the company's outstanding debt will be reduced by approximately $37.9 million."These senior note transactions, combined with continued appreciation in our investment portfolio, have further reduced our net debt position beyond the preliminary estimates communicated for December 31, 2025. We will continue to utilize multiple strategies to reduce debt and invest in our business,” said Bryant Riley, Chairman and Co-Chief Executive Officer of BRCGH.&nbsp;<h2 class="st-heading-2">10-K Report Expected This Month</h2>The company said that it expects to file its 2025 Annual Report on or before the extended deadline of March 31, 2026, and to announce the timing of its earnings release and earnings call next week."The Company values the enormous effort required by its team and business partners to file three Quarterly Reports on Form 10-Q between November 20, 2025 and January 14, 2026.&nbsp; Bringing these filings current while driving strong progress on our annual audit in an accelerated timeframe demonstrates the strength and resolve of our team — and positions us well for the road ahead. We look forward to discussing the Company and taking questions on the earnings call by the end of March,” Riley added.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company are up 52% so far in 2026.&nbsp;

RILY said it repurchased 171,703 units of its 5.0% senior notes due 2026 (RILYG) for approximately $4.0 million in cash. 

RILY Stock Rallies After-Hours – How Much Of Its Debt Is Reduced By Latest Senior Note Transactions?

The company said upon closing of the final transaction with an institutional investor its outstanding debt will be reduced by approximately $37.9 million.

<ul class="summary-bullets"><li>The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;</li><li>The company said that its gross margin for Q4 was at 13.4%, compared to gross margin of 15.3% from year-ago.&nbsp;</li><li>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;</li></ul>FreightCar America shares slumped 19% during extended hours of trading on Monday as it reported a decline in its fourth quarter revenue.&nbsp;The company said its revenues in Q4 came at $125.6 million,&nbsp;lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period.&nbsp;The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>The company posted a fall in its profit in Q4. It reported adjusted net income of $4.9 million, or $0.16 per share, compared to $0.21 per share from the year-ago quarter. RAIL also missed profit expectations of $0.19 per share, as per Fiscal.ai.&nbsp;“In 2025, FreightCar America executed with discipline amid a challenging industry environment, delivering revenue in line with our expectations while producing exceptional profitability,” said Nick Randall, President and Chief Executive Officer of FreightCar America.The company said that its gross margin was at 13.4% with gross profit of $16.8 million, compared to gross margin of 15.3% with gross profit of $21.0 million in the fourth quarter of 2024.&nbsp;<h2 class="st-heading-2">Outlook</h2>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;“As we enter 2026, we remain focused on converting backlog into profitable deliveries while continuing to invest for growth,” Randall said.&nbsp;“Looking ahead to 2026, our guidance reflects ongoing industry uncertainty while reinforcing our confidence in the underlying strength and resilience of the business,” said Mike Riordan, Chief Financial Officer of FreightCar America.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RAIL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen nearly 11% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Freightcar Americs said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024. 

FreightCar America Slumps 21% As Q4 Results And FY26 Disappoints Investors

The company said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period. 

<ul class="summary-bullets"><li>AN2 Therapeutics is expected to sell more than eight million shares of common stock at $2.85 per share.</li><li>The private placement includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital.</li><li>The stock has gained more than&nbsp;500% over four sessions since the company announced positive results for its blood cancer treatment.</li></ul>Shares of AN2 Therapeutics (ANTX) surged more than 110% on Monday, after the clinical-stage biopharmaceutical company announced that it signed a securities purchase agreement for a private placement expected to raise about $40 million in gross proceeds.<a href="https://stocktwits.com/symbol/ANTX">ANTX shares</a> recorded their biggest-ever intraday gains.As part of the deal, AN2 Therapeutics will sell 8.25 million shares of common stock at $2.85 per share, which was also the stock’s closing price on Friday. The company also offered investors the option to purchase pre-funded warrants to acquire up to 5.79 million additional shares at nearly the same price, with an exercise price of&nbsp;$0.00001 per share.The private placement is expected to close on March 10, 2026, and includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital, along with other new and existing shareholders. AN2 Therapeutics did not disclose how it plans to use the proceeds from the offering.<h2 class="st-heading-2">500% Rally After Epetraborole Update</h2>The stock has been on an extraordinary rally, adding nearly 500% over four sessions since the company announced plans to further develop its drug epetraborole into a Phase 2 proof-of-concept study for patients with Polycythemia Vera (PV) who rely on phlebotomy treatments.PV is a blood cancer that causes the bone marrow to produce too many red blood cells, increasing the risk of serious complications such as blood clots.Last week, AN2 Therapeutics said that its oral epetraborole produced consistent and sustained reductions in hematocrit across several studies involving healthy volunteers and other patient groups. The company expects to begin the Phase 2 study in the third quarter of 2026 and plans to provide initial trial updates by the following quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ANTX_jpg_31ad151992.webp" alt="ANTX.jpg">One user highlighted the various resistance levels, speculating that the stock could climb as high as $108.<stembedurl>https://stocktwits.com/M105/message/647014265</stembedurl>However, another expressed confusion over the “bullish excitement.”<stembedurl>https://stocktwits.com/Tradeforlosses/message/647018987</stembedurl>Year-to-date, the stock has gained more than 400%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iran-warns-of-crude-hitting-200-a-barrel-if-energy-infrastructure-is-targeted-report/cZdVpreRIIr">Iran Warns Of Crude Hitting $200 A Barrel If Energy Infrastructure Is Targeted: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Tevogen CEO Ryan Saadi said in a letter to shareholders on Friday that the company is “actively evaluating” potential acquisitions to drive value.“If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time,” the CEO said.As <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/06/3251264/0/en/Letter-to-Shareholders-from-CEO-Dr-Ryan-Saadi.html">per</a> the CEO, the combined entities under consideration for acquisition may generate aggregate annual revenues in excess of $50 million, based on preliminary evaluations.<h2 class="st-heading-2">Proposed Deals</h2>The CEO’s letter comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.If the deal with Apozel goes through, it could provide Tevogen with an established generics platform, the company had said. This includes 11 FDA-approved generic products for the U.S. market and others awaiting approval by the FDA or currently under development.Tevogen is also actively considering other transactions, the company said earlier this week, while expressing its interest in domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers.Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization.Earlier this week, the company also said that its Board has approved a reverse stock split of its common stock at a ratio of 50 for 1 to regain compliance with Nasdaq’s $1 minimum bid price requirement. The stock began trading on a split-adjusted basis on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVGN stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/TVGN">TVGN stock</a> has erased nearly 87% of its value over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lnth-stock-up-after-hours/cZdLQ3SRI4B">Why Is LNTH Stock Up After Hours?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions 

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWC News

IWCiShares Micro-Cap ETF